Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Healthcare

The GLG Healthcare Practice provides access to a global network of more than 55,000 experts from across the entire healthcare industry including physicians, researchers, scientists, and healthcare industry executives.

The Healthcare Practice provides insight into issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors.

Leading Experts on Healthcare

 
David Ziolkowski, Sr Vice President and Chief Information Officer, Sampson Regional Medical CenterDavid Ziolkowski
Sr Vice President and Chief Information Officer
Sampson Regional Medical Center

David Ziolkowski is Senior Vice President and Chief Information Officer at the Sampson Regional Medical Center located in Clinton, NC. He manages over a dozen technical and non-technical departments within the hospital, expanding his role to Senior Vice President, Support Services and Information Management....

Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...

Richard Anthony, PhD, Board member, Janus Pharmaceuticals, Inc.Richard Anthony, PhD
Board member
Janus Pharmaceuticals, Inc.

Richard Anthony, PhD, is the Chief Executive Officer at Catalyst Pharma Group, Inc., California, a contract research organization providing clinical development, regulatory and licensing representative services for pharmaceutical and biotechnology companies. He also serves as the Board Member of Janus...

Ara Dikranian, MD
Partner
San Diego Arthritis Medical Clinic

Ara Dikranian, MD, is a Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in Internal Medicine and Rheumatology. He completed his rheumatology training at the University of California San Diego. He has...

Samir Mehta, MD
Orthopaedic Surgeon
Hospital of the University of Pennsylvania - CC

Samir Mehta, MD, is an Orthopaedic Surgeon at the Hospital of the University of Pennsylavnia. Previously, he was an Instructor at Harborview Medical Center, and Orthopaedic Surgeon and Assistant Professor of Orthopaedic Surgery in the Division of Orthopaedic Trauma at the University of Pennsylvania...

View All Leading Experts in Healthcare

GLG Study Groups in Healthcare(?)

View All Study Groups in Healthcare

GLG NewsSM Analyses in Healthcare(?)

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
By Martin Gold, Principal, Technology Access Partners, LLC

Conmed has indicated that sales of its devices have fallen partially due to the budget tightening at hospitals. While the company minimized the this issue in their statement it is just the tip of the iceberg.

By Robert Boorstein, MD, PhD, Director of Pathology, Bellevue Hospital Center

This study is one that adds to an increasing body of evidence linking specific molecular testing to treatments with expensive and potentially dangerous antichemotherapeutic agents.

As a medical oncologist, I would want to know how folfox/erbitux in k ras wild patients fared against the standard of folfox/avastin for metastatic first line patients. Stephen Schreibman, MD

Response Genetics, Inc. Signs Amendment to Its Master Service Agreement With GlaxoSmithKline (GSK) as Preferred Provider of Genetic Testing Services. The sub-text is that GSK is preparing to "package" their targeted drugs with tests to identify the target! 

Placebo controlled trial,  LABA  is expected to show better lung functions than placebo in the trial Comparison more meaningful when compared with existing  LABA which acts for 12 hours Optimum duration of the trial to see whether lung functions are well maintained over a period of time....

View All GLG News in Healthcare

Request a Project







*Inquiries subject to client acceptance process

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

GLG Clients have access to 55,000+ Healthcare Members Globally:

Healthcare Providers
33,000+
Healthcare Industry Experts 17,000+
Cardiologists
2,500+
Hospital Administrators
1,700+
Pharmacists
1,200+

Become a Council Member

Analytics